Intuitive Surgical, Inc. $ISRG Shares Acquired by Greenfield Seitz Capital Management LLC

Greenfield Seitz Capital Management LLC lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 56.1% in the third quarter, Holdings Channel reports. The firm owned 22,096 shares of the medical equipment provider’s stock after purchasing an additional 7,945 shares during the period. Intuitive Surgical makes up about 2.6% of Greenfield Seitz Capital Management LLC’s investment portfolio, making the stock its 9th biggest position. Greenfield Seitz Capital Management LLC’s holdings in Intuitive Surgical were worth $8,985,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE raised its holdings in Intuitive Surgical by 3.3% in the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after buying an additional 116,292 shares during the period. Bank of New York Mellon Corp acquired a new position in Intuitive Surgical during the second quarter valued at approximately $1,335,753,000. Amundi grew its stake in Intuitive Surgical by 8.6% during the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after buying an additional 193,096 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in Intuitive Surgical by 95.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock worth $970,635,000 after buying an additional 1,027,475 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Intuitive Surgical by 10.8% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,893,485 shares of the medical equipment provider’s stock worth $769,948,000 after acquiring an additional 184,044 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other news, SVP Patricia L. Wadors sold 1,078 shares of the firm’s stock in a transaction that occurred on Friday, October 23rd. The shares were sold at an average price of $443.80, for a total transaction of $478,416.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 4,047 shares of the firm’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $453.21, for a total transaction of $1,834,140.87. Following the sale, the vice president directly owned 1,026 shares of the company’s stock, valued at $464,993.46. The trade was a 79.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 38,778 shares of company stock worth $16,814,967 over the last ninety days. Company insiders own 0.60% of the company’s stock.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $436.87 on Tuesday. The business has a 50-day moving average of $402.70 and a 200-day moving average of $433.43. The company has a market capitalization of $151.44 billion, a PE ratio of 52.83, a P/E/G ratio of 3.06 and a beta of 1.46. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping the consensus estimate of $2.65 by $0.35. The business had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The company’s revenue was up 21.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.40 earnings per share. On average, equities analysts expect that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on ISRG shares. Oppenheimer reissued an “outperform” rating and issued a $500.00 target price on shares of Intuitive Surgical in a research note on Wednesday, October 21st. KeyCorp reiterated an “overweight” rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Leerink Partners set a $503.00 price target on Intuitive Surgical and gave the company an “outperform” rating in a report on Wednesday, October 21st. Royal Bank Of Canada cut their price objective on Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 21st. Finally, Piper Sandler restated an “overweight” rating on shares of Intuitive Surgical in a research note on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $493.54.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.